Evidence map›Paper›PMID 39873695›Full record

Observational studyEuropean heart journal2025

Tricuspid regurgitation and outcomes in mitral valve transcatheter edge-to-edge repair.

Shingo Matsumoto, Yohei Ohno, Satoshi Noda, Junichi Miyamoto, Norihiko Kamioka, Tsutomu Murakami, Yuji Ikari, Shunsuke Kubo, Yuki Izumi, Mike Saji and 18 more

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in European heart journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Observational
  3. Worsening tricuspid regurgitation following a successful mitral valve procedure: how to manage.European heart journal supplements : journal of the European Society of Cardiology · 2026
    Article
  4. Review
  5. Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Shingo MatsumotoDepartment of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan.
Yohei OhnoDepartment of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan.ORCID 0000-0003-4203-7613
Satoshi NodaDepartment of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan.
Junichi MiyamotoDepartment of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan.
Norihiko KamiokaDepartment of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan.
Tsutomu MurakamiDepartment of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan.ORCID 0000-0002-5164-1620
Yuji IkariDepartment of Cardiology, Tokai University School of Medicine, 143 Shimokasuya, Isehara 259-1193, Japan.
Shunsuke KuboDepartment of Cardiology, Kurashiki Central Hospital, Kurashiki, Japan.
Yuki IzumiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.
Mike SajiDepartment of Cardiology, Sakakibara Heart Institute, Tokyo, Japan.ORCID 0000-0003-2057-109X
Masanori YamamotoDepartment of Cardiology, Toyohashi Heart Center, Toyohashi, Japan.
Masahiko AsamiDivision of Cardiology, Mitsui Memorial Hospital, Tokyo, Japan.ORCID 0000-0002-2102-033X
Yusuke EntaDepartment of Cardiology, Sendai Kosei Hospital, Sendai, Japan.ORCID 0000-0003-1931-1012
Shinichi ShiraiDepartment of Cardiology, Kokura Memorial Hospital, Kitakyushu, Japan.
Masaki IzumoDepartment of Cardiology, St. Marianna University School of Medicine, Kawasaki, Japan.
Shingo MizunoDepartment of Cardiology, Shonan Kamakura General Hospital, Kamakura, Japan.
Yusuke WatanabeDepartment of Cardiology, Teikyo University School of Medicine, Tokyo, Japan.
Makoto AmakiDepartment of Heart Failure and Transplant, National Cerebral and Cardiovascular Center, Suita, Japan.
Kazuhisa KodamaDivision of Cardiology, Saiseikai Kumamoto Hospital Cardiovascular Center, Kumamoto, Japan.
Junichi YamaguchiDepartment of Cardiology, Tokyo Woman's Medical University, Tokyo, Japan.ORCID 0000-0003-0967-0978
Toru NaganumaDepartment of Cardiology, New Tokyo Hospital, Chiba, Japan.ORCID 0000-0002-4501-1358
Hiroki BotaDepartment of Cardiology, Sapporo Higashi Tokushukai Hospital, Sapporo, Japan.
Masahiro YamawakiDepartment of Cardiology, Saiseikai Yokohama City Eastern Hospital, Yokohama, Japan.
Hiroshi UenoSecond Department of Internal Medicine, Toyama University Hospital, Toyama, Japan.
Kazuki MizutaniDivision of Cardiology, Department of Medicine, Kindai University Faculty of Medicine, Osaka, Japan.
Daisuke HachinoheDivision of Cardiology, Sapporo Cardio Vascular Clinic, Sapporo, Japan.
Toshiaki OtsukaDepartment of Hygiene and Public Health, Nippon Medical School, Tokyo, Japan.
Kentaro HayashidaDepartment of Cardiology, Keio University School of Medicine, Tokyo, Japan.ORCID 0000-0002-1750-1982

Funding

Daiichi Sankyo CompanyEdwards Lifesciences
6 · The paper itself

Abstract

BACKGROUND AND

aimsThe association between periprocedural change in tricuspid regurgitation (TR) and outcomes in patients undergoing mitral transcatheter edge-to-edge repair (M-TEER) is unclear. This study aimed to examine the prognostic value of TR before and after M-TEER.

methodsPatients in the OCEAN-Mitral registry were divided into four groups according to baseline and post-procedure echocardiographic assessments: no TR/no TR (no TR), no TR/significant TR (new-onset TR), significant TR/no TR (normalized TR), and significant TR/significant TR (residual TR) (all represents before/after M-TEER). Tricuspid regurgitation ≥ moderate was defined as significant. The primary outcome was cardiovascular death or heart failure hospitalization. Tricuspid regurgitation pressure gradient was also evaluated.

resultsThe numbers of patients in each group were 2103 (no TR), 201 (new-onset TR), 504 (normalized TR), and 858 (residual TR). Baseline assessment for TR and TR pressure gradient was not associated with outcomes after M-TEER. In contrast, patients with new-onset TR had the highest adjusted risk for the primary outcome, followed by those with residual TR [compared with no TR as a reference, hazard ratio 1.83 (95% confidence interval: 1.39-2.40) for new-onset TR, 1.45 (1.23-1.72) for residual TR, and 0.82 (0.65-1.04) for normalized TR]. Similarly, from baseline to post-procedure, TR pressure gradient changes were associated with subsequent outcomes after M-TEER. New-onset and residual TR incidence was commonly associated with dilated tricuspid annulus diameter and atrial fibrillation.

conclusionsPost-procedural TR, but not baseline TR, was associated with outcomes after M-TEER. Careful TR assessment after the procedure would provide an optimal management for concomitant significant TR in patients undergoing M-TEER.

Indexed as

Mitral Valve InsufficiencyTricuspid Valve InsufficiencyAgedAged, 80 and overCardiac CatheterizationFemaleHeart FailureHeart Valve Prosthesis ImplantationHumansMaleMiddle AgedPostoperative ComplicationsPrognosisTreatment OutcomeMitral regurgitationMitral valveTranscatheter edge-to-edge repairTricuspid regurgitation

Identifiers

PMID39873695
PMCPMC11997546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.